• Lilly reported positive topline results from the Phase 3 TRANSCEND-T2D-1 trial of retatrutide, an investigational GIP/GLP-1/glucagon triple receptor agonist, in adults with type 2 diabetes inadequately controlled with diet and exercise.
• At 40 weeks, retatrutide reduced A1C by 1.7% to 2% across doses versus a 0.8% reduction with placebo (efficacy estimand).
• Participants receiving retatrutide 12 mg lost 16.8% of body weight at 40 weeks versus 2.5% with placebo (efficacy estimand).
• Common adverse events with retatrutide included nausea (up to 26.5%) and diarrhea (up to 26.3%).
• Detailed results are scheduled to be presented at the American Diabetes Association Scientific Sessions in June and published in a peer-reviewed journal.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603190645PR_NEWS_USPR_____DE13934) on March 19, 2026, and is solely responsible for the information contained therein.